Circulating cell adhesion molecules level in type 2 diabetes mellitus and its correlation with glycemic control and metabolic syndrome: A case-control study

Background: Early detection of high levels of endothelial biomarkers may help in the design of new strategies to prevent many disease complications, as these biomarkers could enable early prediction of endothelial dysfunction and activation. Objectives: This study aimed to detect the level of circulating cell adhesion molecules (ICAM-1, VCAM-1) in diabetic patients and to investigate its relation to glycemic control, duration of diabetes mellitus, and metabolic syndrome. Materials and Methods: Age and sex-matched case-control study design was adopted, the case group involved (type 2 diabetes mellitus on oral hypoglycemic agent only and free from other medical problems), and the control group was (the healthy people without a family history of diabetes mellitus). The samples were collected between November 2021 and May 2022. Both ICAM-1 and VCAM-1 were measured in both groups. Results: A total of 160 individuals were involved (80 cases and 80 controls). The level of both ICAM-1/VCAM-1 was higher in patients with type 2 diabetes mellitus with a value of P <0.0001. There was a strong association between ICAM-1, VCAM-1, and HbA1c. As the duration of the disease increases, the level of these molecules increases. The level of VCAM-1 in patients with metabolic syndrome was very high, whereas for ICAM-1 a slight increase was observed. Conclusion: Circulating cell adhesion molecules can be considered as a marker for detecting the risk of occurrence of diabetes mellitus and the level of these markers can be helpful in follow-up of cases with diabetes and giving a guide for risk of occurrences of metabolic syndrome.